STIM
Neuronetics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.88
+5.88%Year over year
Reported trailing growth
- Revenue
- +39.6%
- EBITDA
- +45.2%
- EBIT
- +40.3%
- EPS
- +61.9%
- Free cash flow
- +71.6%
- Operating cash flow
- +73.5%
Forward estimates
Based on analyst estimates
- Revenue
- +8.9%
- EBITDA
- +34.6%
- EPS
- +24.6%
Three-year CAGR
- Revenue
- +31.8%
- EBITDA
- +21.1%
- EBIT
- +9.0%
- Net income
- +10.8%
- EPS
- +57.2%
- Free cash flow
- +34.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026